

HEALTH TECH DISRUPTOR BUILT  
FOR TRANSFORMATION

**MEDIVOLVE.**  
**INVESTOR**  
**PRESENTATION.**

---

# DISCLAIMER

---

This presentation of Medivolve Inc. ("Medivolve" or the "Company") is for informational purposes only and does not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities of the Company. The information contained herein is subject to change without notice and is based on publicly available information, internally developed data and other sources. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances.. An investment in the securities of Medivolve is speculative and involves a number of risks that should be considered by a prospective investor.

The information contained in this presentation is not directed to persons or entities resident in the United States and does not constitute an offer or solicitation by anyone in the United States or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation, unless otherwise exempt from United States securities legislation. This presentation does not constitute an offer of securities, and no offer or sale of securities will be conducted in any jurisdiction in which such offer or sale is prohibited.

THE SECURITIES DESCRIBED IN THE PRESENTATION HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 (THE "SECURITIES ACT"), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. AND THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.

This presentation includes market and industry data that has been obtained from third party sources. The Company believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third party sources referred to in this presentation or ascertained the underlying assumptions relied upon by such sources. References in this presentation to research reports, results of clinical trials or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article.

**FORWARD-LOOKING STATEMENTS** Certain statements in this presentation are "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as "expect", "seek", "endeavour", "anticipate", "plan", "estimate", "believe", "intend", or stating that certain actions, events or results may, could, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be "forward-looking statements", including, without limitation, statements pertaining to the global market opportunity for testing kits, the Company's expansion plans and the timing thereof, the price at which testing kits may be sold and expected margins, regulatory approval for the use of testing kits and the Company's long-term opportunities. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made and involve significant known and unknown risks, uncertainties and assumptions which could cause actual results or events to differ materially from those presently anticipated. Such assumptions include, without limitation, the Company partnering with established medical distribution companies, the use of testing kits will receive regulatory approval, market acceptance of testing kits and businesses and other organizations will require large-scale testing protocols. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, competition in the market, the Company failing to obtain necessary regulatory approvals, the Company electing not to proceed with its expansion plans or not having the necessary funds to do so and the Company not being able to secure maintain appropriate distribution partnerships. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this presentation. Investors should not place undue reliance on these forward-looking statements. Because of the risks, uncertainties and assumptions contained herein, forward-looking statements should not be read as guarantees of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future. Although the forward-looking statements contained in this presentation are based upon what the Company's management currently believes to be reasonable assumptions, the Company makes no assurances that actual results, performance or achievements will be consistent with these forward-looking statements. The forward-looking statements in this presentation are made as of the date of this presentation. Except as required by law, the Company does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances.



# ABOUT US AND OUR FUTURE.

## WHAT WE DO

Medivolve is a publicly traded healthcare company that seeks out disruptive technologies, ground-breaking innovations and exclusive partnerships to transform human health management.

With a seasoned executive team and renowned global advisors that provide expertise across industries, Medivolve offers investors a diversified investment in the COVID-19 medical space across geographic regions and three focus areas: detection, prevention, and treatment.



## TICKERS

NEO: MEDV  
OTC: COPRF  
FRA: 34C1



## 2021 FORECASTED REVENUE:

\$60M



# BUSINESS PHILOSOPHY.

## OUR WHY

Born out of the Covid-19 pandemic and as the urgent need to address gaps in the nation's fragmented, overly complex and expensive health system, our model is poised to create a full-circle solution that makes it easier and faster to identify, treat, and possibly prevent medical issues.

Powered by AI, our technology platform works together with our diagnostic labs, pharmacies and physicians to close the gap between diagnosis and treatment, empower people with more control over their personal health and achieve a continuity of care never seen before.



**TRANSFORM**

### BUILT FOR TRANSFORMATION

We're building a med-tech platform to not only change the way we approach global health crises, but the future of human health management.



**CREATE**

### CREATE HEALTHIER LIVES

Our model aims to create a full-circle healthcare solution that closes the gap between diagnosis and treatment.



**INSPIRE**

### INSPIRE THE NEW FUTURE (OF HEALTHCARE)

We are striving to achieve a continuity of care never seen before.



# BUILT FOR TRANSFORMATION

We're building a med-tech platform to not only change the way we approach global health crises, but the future of human health management.

[➤ NEXT](#)





# BUILT FOR TRANSFORMATION.

Out of our greatest times of crises comes opportunity, and the COVID-19 pandemic is no different. Forced to rethink, relearn and ultimately, reimagine a better way for our healthcare system, Medivolve was born out of this revolution, and is BUILT FOR TRANSFORMATION.

For the past two years, Medivolve has focused on seeking out disruptive technologies, new innovations, and exclusive partnerships to help combat the far-reaching impact of COVID. Our Collections Sites play an important role in recovery by giving all Americans access to fast, accurate, and inexpensive clinical testing when and where they need it, be it the local shopping center, convenience store or even the gas pump.

Our testing centers are just the beginning. We're bringing together a powerful team of clinicians, pharmacists, mathematicians, computer scientists, and engineers to build a medical technology platform that will not only change the way we approach the global health crises before us, but the future of human health management overall.



# FLATTENING THE CURVE ONE CUBE AT A TIME.

05

## WHAT IT IS

---

Wholly owned subsidiary Collection Sites has 37 COVID-19 testing sites across the U.S. Each site (or cube) is a complete and versatile solution for the ultra-high demand COVID-19 testing marketing in the U.S. The testing centers offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

## STRATEGIC GROWTH IMPERATIVE

---

Experts estimate increasing levels of already ultra-high demand for rapid COVID-19 testing as Americans re-enter the workforce and schools. Analysts view strong levels of testing demand to remain until 2022.

Beyond COVID-19 testing, our Collection Sites are the underpinning for our model. We're partnering with pharma companies and labs to create a full-circle health management solution that draws from our technology to deliver smarter, automated diagnostics that will change the way we approach patient care.

## WHY IT MATTERS

"Speed and accuracy are vital for a comprehensive testing program. Rapid antigen testing can play a vital role. One needs to know do you have the virus. That is best determined by seeing if genetic material is present via PCR. These tests have a bottleneck and results are slow and the tests are expensive. The next information to know is can you detect any viral antigen. And finally what is important to know for each and every one of us is: Has your immune system fought back. This is most easily determined by antibody testing, which is fast, accurate, inexpensive, available in pop up stations and key to a full understanding of what is happening in your own body. The results also inform us of a community's experience as a society as we live within a pandemic viral environment." – Lawrence Steinman, MD, Medical Advisor, Medivolve

## COLLECTION SITES

# A complete and versatile solution for the ultra-high demand COVID-19 testing marketing in the U.S.

Wholly owned subsidiary Collection Sites has 37 COVID-19 testing sites across the U.S.

Collection Sites provides quick and convenient COVID-19 testing in conjunction with a CLIA registered lab, including rapid antigen, PCR and rapid antibody tests with insurance coverage options.

**US \$1M**  
**AVERAGE MONTHLY REVENUE**



# \$0 Out-Of-Pocket COVID-19 TESTING

**A Mission to Test America....  
Every Person, Every Week.**

Understanding the difficult situation that we are facing as a nation, an assembly of top companies in the industry have combined their knowledge and resources to help businesses create the safest environment possible for employees to return to work by offering COVID-19 testing to everyone.

Medivolve provides \$0 out-of-pocket COVID-19 testing to anyone with recent exposure or symptoms. Patients simply need to provide their insurance information or truthfully declare they are uninsured and the third-party laboratory will bill patient insurance or receive reimbursement through associated government programs for the testing of uninsured patients. Patients and Employers will not be billed.

medivolve<sup>+</sup> MassLabs



Clinical  
Laboratory  
Improvement  
Amendments




## COLLECTION SITES

# COVID-19 TESTING: ANTIBODY, RT-PCR & ANTIGEN

**Patients enter the Pop-U sites and can access three different types of COVID-19 testing.**

(1) Antibodies are formed by the body to fight infections. Immunoglobulin M (IgM) is the first antibody that is formed against a germ, so it appears on tests first, usually within 1-2 weeks. The body then forms immunoglobulin G (IgG), which appears on tests about 2 weeks after the illness starts. IgM usually disappears from the blood within a few months, but IgG can last for years.



### RAPID ANTIBODY BLOOD TEST

Antibody (Serology) tests look for SARS-CoV-2 IgM & IgG antibodies<sup>1</sup> in the blood to determine if there was a past infection.

A blood sample is taken with immediate results provided, but will also be sent to a lab for certified testing results.

What does a positive test result mean? A positive test means the person was infected with COVID-19 in the past and their immune system developed antibodies to try to fight it off.



### RT-PCR TEST

RT-PCR tests are real-time reverse transcription polymerase chain reaction tests that look for SARS-CoV-2 virus genetic material to determine if the person has an active infection.

A nasal or throat swab is taken by a healthcare provider and tested. Swabs are sent to a lab for testing results.

What does a positive test result mean? A positive RT-PCR test means that the person being tested has an active COVID-19 infection.



### ANTIGEN TEST

Antigen tests look for pieces of proteins that make up the SARS-CoV-2 virus to determine if the person has an active infection.

In most cases, a nasal or throat swab is taken by a healthcare provider and tested. Swabs are sent to a lab for testing results.

What does a positive test result mean? A positive antigen test means that the person being tested has an active COVID-19 infection.

# COVID-19 Testing – How It Works.

## Rapid Antibody Blood Test



### Finger Prick

Remove protective cap from blue needle and pierce the tip of your finger.

Squeeze your finger to produce enough blood for two drops.



### Test Card

Collect blood with disposable dropper provided. Release **TWO** drops of blood in the bottom collection area of the test card, followed by **TWO** drops of the Diluent.

## RT-PCR Test



1. Samples are collected from the nose or throat of a patient using a swab and are mixed with chemical reagents



2. Samples are put in a machine that duplicates the genetic material and detects its presence

## Antigen Test



1. Peel off aluminum foil seal and rotate the swab inside the extraction vial vigorously at least 5 times



2. Remove the swab, close the vial by pushing the cap onto the vial and squeeze the vial gently to release 3 drops of sample to the sample well

Patients are assisted by lab assistants in administering tests which can take 8-10 minutes

Once tests are performed, patients can leave the facilities while samples are sent to certified Alcala Labs

After testing, Collection Sites transfers communication and customer service responsibilities to Alcala Labs including follow-up of results with patients

# COVID-19 TESTING

## Quick Certified Results



### Accuracy

- ✓ A 95%–98% agreement of positive and negative results



### Quick Results (rapid antibody test only)

- ✓ Preliminary results within 10 minutes after taking the test
- ✓ Certified lab results next day (subject to change based on volume)



### Certified Results (both tests)

- ✓ Clinically verified results through CLIA certified lab partner Alcala Labs
- ✓ Confirmation sent via email or text through a HIPAA-compliant patented software



**MARBELLA PHARMACY**

# EXPANDING OUR PORTFOLIO OF PHARMACY ACQUISITIONS.



## WHAT IT IS

---

Located in San Juan Capistrano, California, Marbella is an open-door retail pharmacy specializing in traditional medication and non-sterile compounded products, immunizations, and specialty and maintenance medications. Marbella Pharmacy also provides no cost door-to-door prescription delivery service and is reputed for servicing the underserved and worker's compensation patients. The pharmacy is CalVax approved and is eligible to participate in the California COVID-19 Vaccination. It is in the process of attaining vaccine allocations from the State of California.

## STRATEGIC GROWTH IMPERATIVE

---

This acquisition advances Medivolve's growth strategy and expands its ability to deliver patient care through immediate access to pharmaceutical distribution throughout the state of California.

## WHY IT MATTERS

---

"With Marbella, we have access to distribute pharmaceuticals, and soon COVID-19 vaccinations in the fifth-largest economy in the world. We will continue to invest in the resources and partnerships that advance our mission to harness the transformative power of technology to help more people live healthier lives." – David Preiner, CEO, Medivolve

## ABOUT THE TRANSACTION

---

Medivolve will acquire 100% of all outstanding shares of Marbella Pharmacy from the shareholders of the company. In consideration for the acquisition of the Marbella Shares, Medivolve shall pay to Marbella Pharmacy shareholders: (i) a cash payment of US\$200,000 payable 60 days following the closing; (ii) a working capital cash payment of US\$75,000 payable 75 days post closing; and (iii) the issuance of 2,000,000 Medivolve Common Shares.

DAILY PAY

# REOPENING AMERICA: MEDIVOLVE X DAILYPAY.

14

## WHAT IT IS

---

DailyPay is an earned wage access platform. But the platform does so much more than give employees access to their earnings in real-time. The platform changes the way money moves between employer and employee, between merchant and shopper, between financial institution and customer. Now money moves faster and smoother, and benefits each participant equally. DailyPay clients include Target, Kroger, TMobile, Adecco, Six flag, McDonalds, Dollar Tree, HCA Healthcare.

## STRATEGIC GROWTH IMPERATIVE

---

This partnership allows us to capitalize on DailyPay sponsored COVID testing to drive greater visibility of Medivolve products and services to future customers, while garnering local and national press around mission to help America's workforces stay safe and healthy. Depending on final list of DailyPay client partners, we can personalize messaging to speak to their impact on the workforce and why it's not only critical for their personal health, but for us all (e.g., some of DailyPay clients provide jobs for America's other unsung heroes ...the shelf stockers, the bread bakers, waste managers, who ensure our vital household necessities are always available when we need them and that life can continue on with some form of normality amid all of the uncertainty, etc.).

## WHY IT MATTERS

"By humanizing the face and health of workers across the country, we will automatically create emotional resonance with Medivolve as a brand and greater awareness among target audiences (e.g.,investors)."

# CREATE HEALTHIER LIVES

Our model aims to create a full-circle healthcare solution that closes the gap between diagnosis and treatment.

➤ NEXT





# CREATE HEALTHIER LIVES.

We're setting our sights on a longer-term vision because the real war is bigger than one pandemic. In the United States today, one person dies every 36 seconds from cardiovascular disease. There were 2 million more people diagnosed with cancer this year alone. And, over 34 million Americans are living with diabetes. Access to good care, especially in rural communities or low-income areas is hard to come by. Prescriptions are often filled without cross-checking medications, systems don't talk to each other, and patients are blind to their options. If we are to bring about real change, we must first address the systemic issues embedded in our hyper fragmented, antiquated, overly complex, and expensive healthcare system. It's time for a solution, not a band-aid. We need a disruptor.

That's where Medivolve comes in. Our country is in dire need of better, faster methods to convert clinical diagnostic data to actionable therapeutic decisions in order to achieve better patient outcomes, and we're evolving to address the urgency our communities and stakeholders are demanding. We know that won't happen standing still. That's why this next phase of growth is about pivoting the model and putting the pieces together to build a profitable, SaaS-based health-tech company.

As we execute on a plan to get there, we're laser-focused on creating a whole that is truly greater than the sum of its parts. We're advancing the mission under a powerful Medivolve brand umbrella united by a common purpose: to harness the transformative power of technology to CREATE HEALTHIER LIVES.

This requires discipline about where we focus our resources, who we partner with, and where we choose to invest to benefit our business and the industry:

- Leaning into AI and tele-diagnostics to make data smarter, more actionable and intelligent clinical decisions;
- Strategic partnerships and acquisitions with diagnostic labs and pharmacies to create a contained ecosystem that all works together;
- Supporting and testing non-invasive, cost-effective and scalable test collection alternatives like BlowFISH to make testing more accessible to those who need it most; and
- Collaborating with a highly experienced team of executives and advisors including medical professionals, computer scientists, engineers, and mathematicians.

**BLOW FISH**

# MEDIVOLVE AND MARVEL DIAGNOSTICS SUCCESSFULLY COMPLETES FIRST-STAGE CLINICAL TESTING.

17

## WHAT IT IS

---

BlowFISH is a simple, inexpensive, non-invasive, massively-deployable, rapid diagnostic or sentinel system for detecting respiratory illness and airborne viral threats.

## STRATEGIC GROWTH IMPERATIVE

---

Through this partnership, Medivolve is well positioned to deliver shareholder value from its equity position in Marvel Diagnostics and the team's successful development of BlowFISH, a non-invasive exhaled breath diagnostic technology that has cleared the first milestone in a series of clinical tests and has entered the next phase toward applying for an Emergency Use Authorization from the FDA to use the technology to test for the COVID-19 virus.

## WHY IT MATTERS

---

"This is an exciting and important milestone in advancing BlowFISH toward achieving EUA status in testing for COVID-19, and providing a non-invasive, cost-effective and scalable testing alternative to nasal swab solutions currently in market. Making testing more accessible to populations, such as children and the elderly, where it may be difficult to administer a nasopharyngeal swab test, will become important in our transition to resuming daily life in the 'new normal'. Data obtained from BlowFISH powered testing will also further Medivolve's mission to use innovation and artificial intelligence to close the loop in health management for every American."— David Preiner, CEO, Medivolve

## ABOUT THE TRANSACTION

---


Medivolve announced a landmark investment in Marvel Diagnostic in January of 2021, providing up to \$1 million in funding, subject to the achievement of certain milestones, to be used to complete the clinical studies for the BlowFISH collection system and to design and optimize, manufacture and market the device.

BLOW FISH

# THE FUTURE IS BRIGHT.

## DIAGRAM OF INNOVATIVE BLOWFISH DEVICE IN USE

Novel BlowFISH device that captures virus within Exhaled Breath Condensate (EBC).



# ADITXT IMMUNE MONITORING: PROTECTIVE IMMUNITY INTELLIGENCE THAT MATTERS..



## WHAT IT IS

---

Aditxt Therapeutics, Inc. ("Aditxt") is a biotech innovation company with a mission to prolong life and enhance its quality by improving immune system health-specifically by developing technologies focused on immune reprogramming and monitoring.

## STRATEGIC GROWTH IMPERATIVE

---

While vaccinations will decrease the likelihood of contracting COVID-19 and any potential of spreading it, the immunization process differs from person to person. The only way to know if you are truly safe from contracting and spreading COVID is to have insight into your unique immune system. Never have we had access to immunity monitoring technology that is efficient, practical and scalable...until now.

At Medivolve, we're united by a powerful, singular purpose: harnessing the transformative power of technology to create healthier lives. With Aditxt, Medivolve is helping to give people a holistic and empowered view of their personal health and greater control in managing it.

## WHY IT MATTERS

"As the rollout of COVID-19 vaccines progress across the United States, people are going to want to monitor their immunity levels regularly. This will be one of the many ongoing services offered through our future telehealth sites as immune responsiveness will be top of mind for people for the foreseeable future. We are excited to be able to bring this testing modality to our customers and believe it will be a significant revenue contributor over the coming now and in the future." - Doug Sommerville, former CEO, Medivolve

# THE WORLD AWAITS.

## MONITORING AND REPROGRAMMING THE IMMUNE SYSTEM

Using innovative technology developed by world leading research institutions, AditxtScore provides personalized quantitative data to determine protective immunity status.

### How it works:

Samples are collected and shipped to Aditxt's high-complexity CLIA-certified lab. We prep and profile the specimen at our facility upon receipt so you can access your results within 48hrs.



CUSTOMER INFORMATION			SPECIMEN		CLIENT
Name	Customer ID	Specimen ID			Requesting Provider
Test Patient #13	1775-66176	223770			
Gender	Birthdate	Age	Collection Date	Collection Time	Requesting Provider Address
Female	01/11/1984	37	01/28/2021	11:00 AM	
Height	Weight	Feeding Status	Received Date		
5 ft 8 in	160 lbs	N/A	01/29/2021		
BMJ	Previous BMJ	Phone Number	Report Type	Report Date	Client ID
24			Complete	01/30/2021	61040178

### Immune Monitoring for COVID-19\*

- Is there evidence of prior exposure to the SARS-CoV-2 virus? YES
- Is there evidence that a robust immune response developed? YES
- Is there evidence this immune response will protect against COVID-19? YES

\* This report represents a snapshot of your current immune status and may change over time. We recommend regular monitoring of your immunity status every 3-6 months

#### Antibodies directed against different SARS-CoV-2 antigen

	Unlabeled	Detected	Previous Results
Anti-SARS-CoV-2 - RBD IgG $\mu\text{g/L}$	<1000	34567	0.000
Anti-SARS-CoV-2 - RBD IgM $\mu\text{g/L}$	<2000	8765	0.000
Anti-SARS-CoV-2 - RBD IgA $\mu\text{g/L}$	<600	4321	0.000
Anti-SARS-CoV-2 - S1 IgG $\mu\text{g/L}$	<600	18344	0.000
Anti-SARS-CoV-2 - S1 IgM $\mu\text{g/L}$	<600	4567	0.000
Anti-SARS-CoV-2 - S1 IgA $\mu\text{g/L}$	342	0.000	0.000
Anti-SARS-CoV-2 - NP IgG $\mu\text{g/L}$	<6700	9008	0.000
Anti-SARS-CoV-2 - NP IgM $\mu\text{g/L}$	6543	0.000	0.000
Anti-SARS-CoV-2 - NP IgA $\mu\text{g/L}$	432	0.000	0.000

#### Comments

Antibodies against SARS-CoV-2 were detected, indicating that your body's immune system has been activated and has mounted a response to the COVID-19 virus. Your antibody response is robust, as demonstrated by the number of different types of antibodies and their magnitude.

#### Neutralizing Antibodies

	Unlabeled	Detected	Previous Results
SARS-CoV-2 Neutralizing Activity $\mu\text{L}$	<1.00	83	0.00

Additional terms, conditions and restrictions apply. Please visit our website for additional information at [www.aditxtscore.com](http://www.aditxtscore.com).

# AditxtScore™ Provides Vital Answers During Every Stage of the Pandemic (and Beyond).

Do I have the virus?

Have I been exposed?  
Is there evidence of an immune response?  
Is the immune response protective?

Am I developing antibodies in response to the vaccine?  
If so, are the antibodies protective?

Is there evidence that I have developed long-term immunity?

## ON GOING

Early stage of pandemic.

## PRE-VACCINE

Understand if you've developed protective immunity based on prior exposure.

Information to help you make a decision about the vaccine.


## DURING-VACCINE/ EARLY FOLLOW-UP

Is the vaccine working to protect me from contracting COVID-19?

## LONG-TERM FOLLOW-UP


Have I developed a cellular immune response that will protect me long term?

# Reduce False Positives & Negatives.




- ✓ AditxtScore™ has 20-fold increased signal to noise ratio even at higher dilution
- ✓ Enhanced sensitivity for detection over background signal

# Timely Evaluation of Response to Vaccines.







Pfizer dosed on 12/31/20 & 1/21/21



Moderna dosed on 1/10/21 & 2/8/21

- ✓ Detects multiple antibodies to multiple antigens in a single test
- ✓ Has potential to incorporate additional targets (i.e. other viruses) in the same assay
- ✓ Detection of antibody levels before and after vaccination


# Detection of Multiple Isotypes Against Multiple Antigens Increases Sensitivity & Specificity.



Sensitivity/specificity using one antigen (RBD)

Combined 3 antigens

# Comprehensive Evaluation of T Cell Response (v.2.0).



- ✓ Can detect multiple cytokines in a single test with higher sensitivity
- ✓ Determines and differentiates between various types of cellular & Humoral immune responses
- ✓ Simultaneous monitoring of cell activation and levels of cytokine release (e.g., cytokine storms)

# AditxtScore™ Immune Monitoring is the Protective Immunity Testing Solution for...



Laboratories



Cruise lines



Schools &  
Universities



Film, TV Media  
Studios



Airlines



Employers



Nursing Homes



Professional &  
Collegiate Sports

# INSPIRE THE NEW FUTURE OF HEALTHCARE

We are striving to achieve a continuity of care never seen before.

➤ NEXT



# INSPIRE THE NEW FUTURE OF HEALTHCARE.

Our model aims to close the gap between diagnostic data and prescription drugs, bringing data-driven clinical decisioning in a way never seen before, powered by a singular, streamlined technology network. Our direct-to-patient strategy is supported by nearly 50 front line testing cubes where patients have direct access to obtain meaningful clinical diagnostic services. On the B2B side, we'll be able to supply healthcare networks and medical partners with the tools to streamline services all underpinned by our Electronic Health Record platform. By partnering with clinical diagnostic labs and pharmacies, we will create a full-circle health management solution that constantly draws from our technology to deliver smarter, automated clinical decisions that will help eliminate the guesswork, make it easier and faster to treat issues and empower people to take a proactive approach to their health. If we can get the formula right, our revenue model will dramatically improve – we're projecting a potential upside from the \$30 COVID testing cost per patient today, to \$300 to \$500 per patient – a game changer for our business and for communities across America.

This is our new focus, and how we believe we can help achieve the continuity of care this country has never seen before. Imagine a world where managing personal health is as simple and intuitive as checking your Facebook. Where real-time data and analytics powers a system that gets smarter each time and can flag, trace and report critical health data to patients and physicians based on measurable biomarkers derived from each patient. Where the life of an at-risk patient is saved by a notification on a smartphone. Where early detection and prevention become the "new normal" in the future of patient care. Now imagine that happening instantly and at scale – for hundreds of thousands of people.

We have the right tools, team, and information, and today we are laying the foundation to ultimately INSPIRE THE NEW FUTURE of human health management. The opportunity before us is bigger than any one innovation. Together with a new management team, strategic partners, and a purpose-driven culture, we are determined to push the boundaries of what's possible – not just for our business and our shareholders, but for physicians and patients, and for the future of healthcare.



**MYOSIN APP**

# **MEDIVOLVE ACQUIRES INDUSTRY-LEADING ELECTRONIC HEALTH PLATFORM.**



## **WHAT IT IS**

The electronic health record platform is designed to improve patient care and increase collaboration with clinicians through an efficient, cloud-based system. The app streamlines patient intake forms and delivers medical reports through personalized patient portals. Clinical staff members are empowered with a platform to consolidate provider and staff responsibilities to organize patient information before, during, and after interactions. The cloud-based infrastructure eliminates the need for software downloads and specialized hardware, making it easily deployable. Clinical workflows are streamlined in the company's system to minimize the time required to submit orders, share results, and access reports.

---

## **STRATEGIC GROWTH IMPERATIVE**

We're united by a powerful, singular purpose: harnessing the transformative power of technology to create healthier lives. This new platform supports Medivolve's position as a growing health technology and services company.

The app is the foundation of our data-driven AI platform to improve patient care powered by clinical diagnostics, prescription medications, and physician oversight. As we build out the app, we'll be able to streamline our current Covid-19 testing services, vastly improve customer experience, and reduce operating costs.

---

## **WHY IT MATTERS**

"The integration of this incredible platform is a major step forward in Medivolve's evolution from a COVID-19 testing company to a health technology and services company that aims to disrupt the American healthcare system for the long-term," said David Preiner, CEO, Medivolve. "We intend on utilizing this platform to streamline our current testing services, offering an improved customer experience while reducing our operating costs. The implications of this platform extend far beyond COVID-19, and we will work to learn from, and expand on its benefits to provide personalized and effective health services to patients across a variety of use-cases." – David Preiner, CEO, Medivolve

---

## **ABOUT THE TRANSACTION**

Medivolve will acquire a 100% interest in the App from Myosin for consideration of twenty (20) million common shares of Medivolve.

# MEET THE TEAM

We have the right tools, team, and information, and today we are laying the foundation to ultimately **INSPIRE THE NEW FUTURE** of human health management. The opportunity before us is bigger than any one innovation. Together with a new management team, strategic partners, and a purpose-driven culture, we are determined to push the boundaries of what's possible – not just for our business and our shareholders, but for physicians and patients, and for the future of healthcare.

➤ NEXT

# MEDIVOLVE DIRECTORS.

# 31



**DR. BEVERLEY  
RICHARDSON**

**DIRECTOR**  
[Learn more.](#)



**DANIEL BAIZAK**  
**DIRECTOR**  
[Learn more.](#)



**WEN YE**  
**EXECUTIVE CHAIRMAN**  
[Learn more.](#)

# MEDIVOLVE OFFICERS.



**DAVID PREINER**

**CEO**

[Learn more.](#)



**DEBORAH BATTISTON**

**CFO**

[Learn more.](#)



**AARON ATIN**

**Corporate  
Secretary** [Learn  
more.](#)



**WEN YE**

**EXECUTIVE CHAIRMAN**  
[Learn more.](#)

# MEDIVOLVE ADVISORS.



**DR. GLENN  
COPELAND**

**ADVISOR**  
[Learn more.](#)




**DR. JOESEPH  
SUGERMAN**

**ADVISOR**  
[Learn more.](#)



**DR. LAWRENCE  
STEINMAN**

**ADVISOR**  
[Learn more.](#)



**DR. PAULO  
IGLESIAS**

**ADVISOR**  
[Learn more.](#)

# STRATEGIC ADVISORS.



**MICHAEL MCCARTHY**

**ADVISOR**

[Learn more.](#)



**JIM ROGERS**

**ADVISOR**

[Learn more.](#)



**MIKE MANCIAS**

**ADVISOR**

[Learn more.](#)



**RICHARD DOLAN**

**ADVISOR**

[Learn more.](#)

---

## DISCLAIMER - RESCISSION RIGHTS

---

In certain circumstances, purchasers resident in certain provinces of Canada are provided with a remedy for rescission or damages, or both, in addition to any other rights they may have at law, where an offering memorandum (such as this presentation) and any amendment to it contains a misrepresentation. Where used herein, "misrepresentation" means an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement not misleading in light of the circumstances in which it was made. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed by applicable securities legislation.

The following summary is subject to the express provisions of the applicable securities laws, regulations and rules, and reference is made thereto for the complete text of such provisions. Such provisions may contain limitations and statutory defenses not described here on which Medivolve Inc. (the "Company") and other applicable parties may rely. Purchasers should refer to the applicable provisions of the securities legislation of their province for the particulars of these rights or consult with a legal adviser.

The following is a summary of rights of rescission or damages, or both, available to purchasers resident in the province of Ontario, New Brunswick, Nova Scotia and Saskatchewan. If there is a misrepresentation herein and you are a purchaser under securities legislation in Ontario, New Brunswick, Nova Scotia and Saskatchewan you have, without regard to whether you relied upon the misrepresentation, a statutory right of action for damages, or while still the owner of the securities, for rescission against the Company. This statutory right of action is subject to the following: (a) if you elect to exercise the right of action for rescission, you will have no right of action for damages against the Company; (b) except with respect to purchasers resident in Nova Scotia, no action shall be commenced to enforce a right of action for rescission after 180 days from the date of the transaction that gave rise to the cause of action; (c) no action shall be commenced to enforce a right of action for damages after the earlier of (i) 180 days (with respect to purchasers resident in Ontario) or one year (with respect to purchasers resident in Saskatchewan and New Brunswick) after you first had knowledge of the facts giving rise to the cause of action and (ii) three years (with respect to purchasers resident in Ontario) or six years (with respect to purchasers resident in Saskatchewan and New Brunswick) after the date of the transaction that gave rise to the cause of action; (d) with respect to purchasers resident in Nova Scotia, no action shall be commenced to enforce a right of action for rescission or damages after 120 days from the date on which payment for the securities was made by you; (e) the Company will not be liable if it proves that you purchased the securities with knowledge of the misrepresentation; (f) in the case of an action for damages, the Company will not be liable for all or any portion of the damages that it proves do not represent the depreciation in value of the securities as a result of the misrepresentations; and (g) in no case will the amount recoverable in such action exceed the price at which the securities were sold to you. The foregoing is a summary only and is subject to the express provisions of the Securities Act (Ontario), the Securities Act (New Brunswick), the Securities Act (Nova Scotia) and the Securities Act (Saskatchewan), and the rules, regulations and other instruments thereunder, and reference is made to the complete text of such provisions contained therein. Such provisions may contain limitations and statutory defenses on which the Company may rely.

In Manitoba, the Securities Act (Manitoba), in Newfoundland and Labrador the Securities Act (Newfoundland and Labrador) and in Prince Edward Island the Securities Act (PEI) provide a statutory right of action for damages or rescission to purchasers resident in Manitoba, Newfoundland and PEI, respectively, in circumstances where this presentation or an amendment hereto contains a misrepresentation, which rights are similar, but not identical, to the rights available to Ontario purchasers.

Notwithstanding that the Securities Act (British Columbia), the Securities Act (Alberta), and the Securities Act (Québec) do not provide, or require the Company to provide, to purchasers resident in these jurisdictions any rights of action in circumstances where this presentation or an amendment hereto contains a misrepresentation, the Company hereby grants to such purchasers contractual rights of action that are equivalent to the statutory rights of action set forth above with respect to purchasers resident in Ontario.



medivolve<sup>+</sup>

**THANK YOU**